Shares of NeurAxis, Inc. (NRXS) have gained 4.6% since the company reported results for the quarter ended Dec. 31, 2025, against a 0.8% decline in the S&P 500 over the same period. Over the past month, the stock has rallied sharply, gaining 38.5% against the S&P 500’s 5.1% decline.NeurAxis’ Earnings SnapshotNeurAxis reported fourth-quarter 2025 revenues of $968,000, up 27% year over year from $761,000, marking its sixth consecutive quarter of double-digit growth. The revenue increase was driven by a 35% ris ...

Core Viewpoint - EnviroGold Global Limited has appointed Karina Nott as Chief Financial Officer to enhance its executive leadership and support the commercial deployment of its proprietary NVRO Process™ and achieve key commercialization milestones and revenue targets [1][2]. Leadership Appointment - Ms. Nott's appointment is effective March 23, 2026, and is expected to strengthen the company's leadership as it develops a scalable, multi-jurisdictional project pipeline [2]. - The previous Interim Chief Financial Officer, Peter Nguyen, has resigned but will assist with the transition and the 2025 audit [5]. Ms. Nott's Experience - Ms. Nott has over 20 years of international experience in capital markets, financial strategy, and scaling high-growth technology companies [3]. - She has a strong track record in capital raising, having supported significant funding initiatives across Series B and Series C financings, as well as structured transactions [3][4]. - Her most recent role was as VP of Finance at a global satellite-enabled IoT company, where she contributed to capital strategy and international expansion [4]. Company Strategy and Technology - EnviroGold Global focuses on clean technology that recovers high-value metals from sulfidic mine waste and tailings using its NVRO Process™ [6]. - The company's approach aims to provide scalable, lower-impact metal recovery solutions that align with global ESG frameworks and critical-minerals strategies [6].

International expansion is progressing with European dossiers for the PreTRM Global test expected for submission in the coming months to secure CE marking.Operational improvements focused on clinical workflow integration, including peer-to-peer education and digital platforms to drive repeat ordering among early adopters.Strategic focus has shifted toward high preterm birth burden states, with engagement expanding from 6 to 13 states during 2025 to build local market density.Management rebranded 'Medicaid p ...

Core Insights - Ideal Power Inc is advancing towards commercialization of its B-TRAN-enabled products through strategic partnerships and agreements [1][2] - The company has established a multi-year cooperation with Lazzen for circuit protection products, with the first B-TRAN-enabled breaker targeting AI data center customers [1] - A letter of intent has been signed with an Asian power module manufacturer for global production and distribution of B-TRAN-based power modules [1] - Engagements with Stellantis for potential EV contactor programs are progressing, with key deliverables expected by mid-2026 [1] Financial Position - Ideal Power has a growing patent portfolio with 100 issued B-TRAN patents globally and a clean capital structure with no long-term debt [2] - The company raised $12.6 million in capital earlier this year, positioning it well to fund growth initiatives [2] Leadership and Strategy - The CEO has focused on understanding the business state and setting strategic priorities during the first quarter [3] - Direct customer engagement has been emphasized to validate the technology and understand customer perspectives on B-TRAN [4][5] Product Development and Market Entry - The company is supporting lead customers in developing B-TRAN-based products and guiding them through the qualification process [6] - Initial sales orders are expected by the fourth quarter of this year, with a ramp-up planned for 2027 [7] Market Opportunities - Key growth drivers for B-TRAN adoption include solid-state circuit breakers in data centers and battery energy storage systems, with static transfer switches also identified as a potential application [8] Operational Readiness - The company has two foundry partners to ensure robust supply capabilities and is exploring further expansion [10] - A new Chief Operating Officer with extensive semiconductor industry experience has been appointed to enhance operational capabilities [11] Capital Allocation - The recent capital raise will support the expansion of the sales organization, including hiring technical sales resources in Asia and a European sales leader [12]

Core Viewpoint - The article emphasizes that significant capital expenditures often lead to market panic, but historical trends indicate that true turning points in technology industries emerge after the "most expensive investment phase" [1][3]. Group 1: Capital Expenditure Surge - The four major tech giants—Amazon, Alphabet, Meta, and Microsoft—reported a staggering 66% year-on-year increase in capital expenditures, surpassing $200 billion in total [6][3]. - This surge in capital spending is primarily directed towards data center construction, GPU server procurement, power system upgrades, and network infrastructure expansion [6][3]. - For instance, Meta raised its 2025 capital expenditure guidance from $30 billion to $40 billion, resulting in a drop in free cash flow from 35% to 18% [7]. Group 2: Historical Context and Market Reactions - Historical examples, such as the fiber optic construction cycle around 2000 and the mobile internet boom post-2010, show that initial market concerns about overcapacity often give way to significant long-term growth [9][8]. - The current anxiety in the market is reminiscent of past cycles, where initial high capital expenditures led to skepticism about demand matching supply [9][8]. Group 3: Transition to Profitability - The article suggests that the market's focus will shift from "who spends the most" to "who earns the fastest" as capital expenditure growth begins to slow [12][19]. - Analysts believe that the AI arms race is currently in a phase of infrastructure development rather than profitability, indicating that the true commercial value will be realized once the foundational investments are in place [9][10]. Group 4: Future Investment Dynamics - As the infrastructure for AI becomes established, the investment logic will transition from hardware to software and services, marking a shift from "selling shovels" to "gold mining" [15][14]. - Companies like Apple are maintaining financial flexibility by avoiding massive data center investments, while also leveraging AI capabilities through device upgrades and subscription services [16]. Group 5: Key Indicators for Investment - The article highlights the importance of identifying efficiency turning points, such as when AI service revenue growth surpasses capital expenditure growth, as critical indicators for the next investment phase [22][21]. - The transition from the first phase of explosive capital spending to the second phase of revenue realization is anticipated to occur within the next 12-24 months [19][20].

Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Updates NASDAQ:ZLAB | HKEX:9688 © 2026. Zai Lab. All Rights Reserved. This presentation contains forward-looking statements, including statements relating to our strategy and plans; potential of and expectations for our business, commercial products, and pipeline programs; our goals, objectives, and priorities and our expectations under our growth strategy (including our expectations regarding our commercial products and launches, and ...

Leadership Changes - 374Water Inc has announced leadership changes to accelerate the commercialization of its supercritical water oxidation technology, aiming for scalable deployment starting in 2026 [1][3] - Daniel Bogar has been appointed as president and CEO, bringing over two decades of executive experience in finance, strategic business development, and international operations [2][5] Shareholder Engagement - The leadership realignment follows extensive engagement with shareholders, including discussions with long-term investors who filed a Schedule 13D regarding the company's strategic direction [3] Board Composition - Three new directors have been added to the board: Brad Freels, Charles Weiser, and Stephen McKnight, joining existing directors Jim Pawloski and Marc Deshusses [7] - The reconstituted board is focused on scaling the deployment of the AirSCWO platform [8] Leadership Background - Bogar previously served as president and COO of PowerVerde Inc, where he played a key role in the merger with 374Water and has overseen corporate development since then [4][5] - The board expressed confidence in Bogar's ability to lead the company into its next phase of commercialization and growth [5]

Core Insights - Burcon Nutrascience Corporation has transitioned from development-stage operations to commercial scale with its Galesburg production facility, achieving 3Q26 revenue of $739,000, which reflects approximately 107% quarter-over-quarter growth driven by protein sales and production activity [1] - The company entered CY2025 without a production facility but met its revenue target by the end of the year, highlighting the rapid commercialization following Galesburg's launch [1] - Management has established staffing and infrastructure, allowing for incremental volume growth with limited additional fixed costs, which supports operating leverage as throughput increases [1] - Approximately 65-70% of expected growth is tied to existing customers, with over 200 active projects in the pipeline, indicating a strong foundation for recurring revenue expansion [1][6] Revenue Performance - Burcon's revenue increased by 1,100% year-over-year, showcasing significant growth potential [6] - The company anticipates double-digit revenue growth in CY26, further indicating a positive outlook for future performance [6]

Financial Data and Key Metrics Changes - Revenue for Q2 fiscal 2026 was $1.3 million, down from $1.6 million in Q2 fiscal 2025 and $1.4 million in Q1 fiscal 2026 [13] - GAAP net loss for the quarter was $1.9 million, or $0.11 per share, compared to a net loss of $2.9 million, or $0.24 per share in the prior year, and a net loss of $1.5 million, or $0.09 per share in the previous quarter [15] - Adjusted EBITDA loss for the quarter was $917,000, compared to a gain of $647,000 in the same period last year and a loss of $450,000 in Q1 fiscal 2026 [16] - The company closed the quarter with $38.6 million in cash and cash equivalents, an increase of $425,000 from the previous quarter [16] Business Line Data and Key Metrics Changes - Government R&D contracts were the principal source of revenue for the quarter, providing non-dilutive funding for R&D investments [14] - The company is witnessing a shift in customer conversations from interest and evaluation to pricing and planning, indicating progress in commercialization [6] Market Data and Key Metrics Changes - The top four hyperscalers invested over $300 billion in data center CapEx in 2025, expected to surpass $1 trillion by 2029, presenting a significant market opportunity [4] - The mobile market is preparing to adopt short-wave infrared (SWIR) sensors, with Aeluma's manufacturing platform enabling the necessary scale for mass markets [5] Company Strategy and Development Direction - Aeluma is focused on three primary near-term target markets: data centers, mobile, and defense, with ongoing activities across each [5] - The company aims to capitalize on its progress and the growing market horizon while pursuing strategic opportunities to accelerate commercialization [12] - Aeluma's technology is positioned to provide scalable quantum photonic systems, with a focus on integrating highly nonlinear materials on large substrates [10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the momentum building within the company, emphasizing the importance of converting this momentum into customer programs and transitioning to commercialization [19] - The company is actively pursuing strategic government programs that can accelerate commercialization opportunities [14] Other Important Information - Aeluma has expanded its patent portfolio to 35 issued and pending patents, enhancing its competitive advantage [11] - The company has appointed Bouch Nassar as Senior Vice President of Business Development and Product, expected to accelerate the go-to-market strategy [7] Q&A Session Summary Question: What are the end markets that you're getting sales orders for? - Management indicated that sales orders are coming from multiple markets including mobile, AI, data centers, and defense, but specific customer or product information is not being disclosed at this time [22] Question: Is this for receiving or operations or routing or sending of photons? - The current work is primarily focused on generating photons, with interest in building a comprehensive platform for photon management [23] Question: Can you provide more details on the magnitude of customer engagement? - Management noted that the increase in requests for quotations is a positive sign, indicating growing interest in their technology [28] Question: Can you discuss the adoption timeline for SWIR in mobile applications? - While a specific timeline cannot be provided, management noted that the mobile industry is gearing up to adopt SWIR technology for future products [30] Question: What strategic opportunities are being pursued for commercialization? - Management is exploring various pathways to market, including licensing deals and partnerships with supply chain partners [34]

Financial Data and Key Metrics Changes - In Q4 2025, research and development expenses decreased to $6.2 million from $7 million in Q4 2024, reflecting the completion of the SHIELD II Phase 3 trial [15] - General and administrative expenses increased to $1.8 million in Q4 2025 from $1 million in Q4 2024, primarily due to non-cash expenses related to performance-based options [16] - The net loss for Q4 2025 was $8.5 million or $0.41 per share, unchanged from the previous year but improved on a per-share basis from $1.13 in Q4 2024 [16] - For the full year 2025, net loss was $34.2 million or $2.09 per share, compared to a net loss of $29 million or $4.91 per share in 2024 [17] - As of December 31, 2025, the company had $12.9 million in cash and equivalents, with additional gross proceeds of $3.7 million generated from warrant exercises post-quarter [18] Business Line Data and Key Metrics Changes - The company successfully completed the SHIELD II Phase 3 trial for D-PLEX100, achieving its primary and key secondary endpoints [5] - The focus remains on advancing the regulatory pathway for D-PLEX100 and commercial partnership discussions in the U.S. [5][7] Market Data and Key Metrics Changes - The company is engaging with potential U.S. commercial partners that have strong hospital-based commercialization experience [11] - Discussions with partners have progressed to advanced stages, reflecting the strong clinical profile of D-PLEX100 [7] Company Strategy and Development Direction - The company is transitioning from a primarily R&D-focused organization to one preparing for commercialization, with a renewed corporate brand to reflect this change [11][12] - The introduction of Kynatrix technology aims to expand capabilities beyond localized delivery, targeting metabolic diseases with a long-acting GLP-1 receptor agonist program [14] Management's Comments on Operating Environment and Future Outlook - Management believes 2026 could be transformative, with the rolling NDA submission expected to begin by the end of Q1 2026 [9] - Positive feedback from the FDA supports the regulatory pathway for D-PLEX100, with expectations for a rolling NDA submission [6][9] Other Important Information - The company appointed Ms. Brooke Story as chairman of the board in December 2025, bringing extensive experience in medical technology [9] Q&A Session Summary Question: Can you share how discussions around the scope of the label progressed? - The company is targeting an initial label for the prevention of surgical site infections in abdominal colorectal surgery, supported by Phase 3 data [22] Question: Any thoughts on plans for broader label expansion? - There may be opportunities for label expansion into broader abdominal surgical applications as the review process progresses [24] Question: What work is being done to prepare for potential approval of D-PLEX100? - The company is focusing on building awareness, market research, and creating a KOL network to prepare for commercialization [32] Question: How do you view the strategic timing for the GLP-1 program? - The company plans to partner at an early stage, leveraging robust preclinical data to attract interest [35] Question: What factors will play a role in identifying the final partner? - The ideal partner will have broad hospital-based capabilities and presence in the surgical suite [41] Question: What percentage of potential target IDNs would likely include D-PLEX on formulary within the first 12 months after approval? - The uptake will take time, with a few months before seeing meaningful updates, but once on formulary, usage is expected to grow steadily [50]